Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

27.89 -0.15 (-0.53%)
Delayed Quote Updated: 10:06 AM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
Dow Drops 100 Points; US Jobless Claims Fall Further Last Week ↗
U.S. stocks traded mostly lower this morning, with the Dow Jones dropping 100 points on Thursday. 
Via Benzinga
News headline image
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 70% Today? ↗
Amylyx Pharmaceuticals (AMLX) stock is rocketing higher on Thursday following an update from the FDA on its ALS treatment. 
Via InvestorPlace
News headline image
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Stock Trading Halted Today
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
FDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate ↗
 
Via Benzinga
News headline image
The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff ↗
The FDA's advisors will meet Wednesday to discuss the experimental ALS treatment. 
Via Investor's Business Daily
News headline image
Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up — Again ↗
Could this FDA action turn things around for Amylyx in September? 
Via Investor's Business Daily
News headline image
Here's How Citi Views Amylyx Pharma ↗
 
Via Benzinga
News headline image
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday ↗
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
What 4 Analyst Ratings Have To Say About Amylyx Pharma ↗
Within the last quarter, Amylyx Pharma (NASDAQ:AMLX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Why Stealth BioTherapeutics Shares Are Surging Today? ↗
 
Via Benzinga
News headline image
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
News headline image
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
News headline image
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
Via FinancialNewsMedia
News headline image
Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
7 Biotech Stocks to Buy for Q3 ↗
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
News headline image
Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Is Novavax (NVAX) Stock Rallying Today? ↗
Novavax (NVAX) stock is taking off on Tuesday after the vaccine company got approval for the expanded use of its Covid-19 vaccine in Europe. 
Via InvestorPlace
News headline image
Amylyx (AMLX) Stock Spikes 13% as FDA Resumes Discussion of ALS Drug ↗
A new wrinkle in the story of Amylyx Pharmaceuticals' ongoing battle against ALS bodes well for patients, and for AMLX stock holders. 
Via InvestorPlace
News headline image
Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Ra Medical Systems, Inc. (NASDAQ: RMED) shares jumped 69.6% to $0.5240 after the company announced it has received FDA 510(k) clearance for its DABRA 2.0 catheter. 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before. 
Via Investor's Business Daily
News headline image
Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September ↗
The Canadian government has given its approval to AMX0035, a new drug from Cambridge, Massachusetts-based Amylyx Pharmaceuticals Inc. 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
News headline image
82 Biggest Movers From Yesterday ↗
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday. 
Via Benzinga
News headline image
83 Biggest Movers From Yesterday ↗
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.